ESMO 2019 | CRT and Debio1143 for treatment of LA SCCHN

Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland outlines the initial findings in this double-blind randomized phase II trial regarding the use of cisplatin chemoradiation (CRT) plus debio 1143 in the treatment of locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.